
Opinion|Videos|June 25, 2024
Adjuvant RSV Vaccine in Older Adults
Author(s)Carrie Koenigsfeld, PharmD, FAPhA
Carrie Koenigsfeld, PharmD, FAPhA, reviews the pivotal findings from the AReSVi-006 trial that supported the approval of the adjuvanted RSV vaccine, including its efficacy in preventing lower respiratory tract RSV, associated adverse events, and important study limitations that may have influenced the results.
Advertisement
Episodes in this series

Now Playing
- While the follow-up data for the
AReSVi-006 trial have not been published, what key results thus far have led to the approval of the adjuvanted vaccine?- Efficacy of preventing RSV-related lower respiratory tract disease
- Adverse effects
- Trial limitations
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means
2
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
3
First-in-Human In Vivo CAR-T Therapy Shows Encouraging Activity in Relapsed/Refractory Multiple Myeloma
4
Apnimed Submits NDA for AD109 Following Positive Phase 3 Results in Obstructive Sleep Apnea
5



























































































































